The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

HHS Secretary Robert F. Kennedy Jr. threatened to bar NIH scientists from publishing in leading medical journals, saying the ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Goldman Sachs lowered its forecast for the total market for anti-obesity drugs through the end of the decade. Asad Haider, ...

Obesity specialists say first-generation anti-obesity medications often get a ‘bad wrap,’ but these drugs can be effective ...

However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...

Novo Nordisk A/S’s surprise decision to replace Chief Executive Officer Lars Fruergaard Jorgensen has triggered a race to ...